C4 Therapeutics (NASDAQ: CCCC) highlights cemsidomide Phase 1 response rates in RRMM
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
C4 Therapeutics filed a report highlighting new clinical data and investor materials for its IKZF1/3 degrader cemsidomide in relapsed/refractory multiple myeloma. A fully enrolled Phase 1 trial of cemsidomide plus dexamethasone in 73 heavily pretreated patients showed a 53% overall response rate at the 100 µg once-daily recommended Phase 2 dose and 36% across all doses, with some responses deepening over time and minimal residual disease negativity in select patients. Median progression-free survival was 3.9 months and median duration of response was 7.9 months. Safety was characterized mainly by on‑target neutropenia, with 58% experiencing grade 3/4 neutropenia, few dose reductions and no discontinuations attributed to cemsidomide. The company is now enrolling a Phase 2 single‑arm study in fourth‑line and later multiple myeloma and a Phase 1b combination trial with the bispecific antibody elranatamab, while also outlining a broader strategy in oncology and inflammation/neuroinflammation indications.
Positive
- None.
Negative
- None.
Insights
Phase 1 cemsidomide data support continued development but remain early-stage.
The updated Phase 1 results for cemsidomide plus dexamethasone in heavily pretreated multiple myeloma show a 53% overall response rate at the 100 µg recommended Phase 2 dose and 36% across all doses. Responses deepened over time and included MRD-negative complete responses.
Median progression-free survival of 3.9 months and median duration of response of 7.9 months are consistent with a late-line setting. Safety is dominated by on-target neutropenia, with 58% grade 3/4 events, but few discontinuations attributed to cemsidomide, suggesting a manageable profile within this population.
These data justify the ongoing single-arm Phase 2 trial in fourth‑line and later disease and the Phase 1b combination study with elranatamab. Subsequent readouts from these trials, including overall response rate and MRD negativity, will be important to understand how cemsidomide compares with other next‑generation IKZF1/3 degraders.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash runway: to end of 2028
Phase 1 patients: 73 patients
ORR at 100 µg: 53% ORR
+5 more
8 metrics
Cash runway
to end of 2028
Company guidance in June 2026 presentation
Phase 1 patients
73 patients
Cemsidomide + dexamethasone safety population
ORR at 100 µg
53% ORR
Recommended Phase 2 dose for cemsidomide in RRMM
ORR all doses
36% ORR
Cemsidomide + dexamethasone Phase 1 trial
Median PFS
3.9 months
All cemsidomide dose levels in Phase 1
Median DOR
7.9 months
Responders across all cemsidomide doses
Grade 3/4 neutropenia
58% of patients
On‑target hematologic toxicity in Phase 1
Prior therapies
7 prior lines (median)
Heavily pretreated RRMM population
Key Terms
overall response rate, minimal residual disease, recommended Phase 2 dose, targeted protein degradation, +2 more
6 terms
overall response rate financial
"At the RP2D and maximum tolerated dose (100 µg,) cemsidomide achieved a 53% overall response rate (ORR)."
Overall response rate is the percentage of patients in a clinical study whose measurable disease shrinks or disappears after receiving a treatment. Investors watch it like a product’s “hit rate” because higher response rates can signal a drug’s effectiveness, boost chances of regulatory approval and market demand, and affect a company’s future revenue prospects, similar to how a higher batting average suggests a more reliable player.
minimal residual disease clinical
"Minimal residual disease (MRD) negativity was achieved in two patients who achieved a sCR and complete response (CR) at 100 µg."
Minimal residual disease (MRD) is the tiny number of cancer cells that remain in the body after treatment, often too few to show up on standard scans but detectable with very sensitive tests. For investors, MRD is important because it predicts the risk of relapse and can determine whether a therapy is seen as effective, influences regulatory and reimbursement decisions, and affects the size and timing of a drug’s market opportunity—like spotting the last weeds that can make a garden regrow if not removed.
recommended Phase 2 dose clinical
"Data from the Phase 1 trial identified 100 µg as the recommended Phase 2 dose."
Recommended phase 2 dose is the specific drug amount chosen after initial human studies to use in mid-stage clinical trials that assess whether the treatment works and remains reasonably safe in patients. Investors pay attention because that dose determines how convincing the upcoming trial results are likely to be, influences the size, cost and duration of further studies, and affects the chance of regulatory approval and commercial success—much like picking the right test speed to judge a new car's performance without risking damage.
targeted protein degradation technical
"C4 Therapeutics, Inc. (C4T) ... dedicated to advancing targeted protein degradation (TPD) science."
Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.
BCMAxCD3 bispecific clinical
"Initiate and enroll Phase 3 trial of cemsidomide + BCMAxCD3 Bispecific."
IKZF1/3 degrader clinical
"cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone"
An IKZF1/3 degrader is a drug that causes the cellular proteins IKZF1 and IKZF3 to be broken down and removed; these proteins act like on/off switches that help certain blood cancers survive. For investors, this matters because destroying those switches can stop cancer cells and produce measurable clinical benefit, which can drive trial success, regulatory approval and company value, while also carrying the usual development and safety risks; think of it as removing a critical bolt to disable a faulty machine.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________
FORM 8-K
_________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 11, 2026
_________________________________________________________________
(Exact name of Registrant as Specified in Its Charter)
_________________________________________________________________
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s Telephone Number, Including Area Code: (617 ) 231-0700
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 7.01 Regulation FD Disclosure.
On June 11, 2026, C4 Therapeutics, Inc. (the “Company”) posted a a corporate presentation on its website at https://ir.c4therapeutics.com/events-presentations. A copy of the presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
Item 8.01 Other Events.
On June 11, 2026, the Company posted on its website a poster presentation with further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (“RRMM”), to be presented at the European Hematology Association 2026 Congress (“EHA 2026 Congress”). A copy of the poster presentation, which has been published to the “Events & Presentations” section of the Company’s website, is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
On June 11, 2026, the Company also issued a Press Release reporting further analysis from the Phase 1 trial of cemsidomide in combination with dexamethasone for the treatment of RRMM to be presented at the EHA Congress. A copy of the Press Release is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.
Exhibit Number | Description | |||||||
99.1 | Corporate presentation of the Company dated June 2026 | |||||||
99.2 | Poster from C4 Therapeutics, Inc.’s EHA 2026 Congress Presentation, dated June 11, 2026 | |||||||
99.3 | Press release issued June 11, 2026 | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
C4 Therapeutics, Inc. | ||||||||
Date: | By: | /s/ Kendra R. Adams | ||||||
Kendra R. Adams | ||||||||
Chief Financial Officer and Treasurer | ||||||||
Protein degraded. Disease targeted. Lives transformed. June 2026
Forward-looking Statements and Intellectual Property 2 FORWARD-LOOKING STATEMENTS The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.’s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward- looking statements. The forward-looking statements included in this presentation speak only as of the date hereof and are subject to a variety of risks and uncertainties, including those set forth in our most recent and future filings with the Securities and Exchange Commission. Our actual results could vary significantly from those anticipated in this presentation, and our financial condition and results of operations could be materially adversely affected. C4 Therapeutics, Inc., undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise. This presentation also contains estimates, projections and other information concerning the markets for C4 Therapeutics, Inc.’s product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions and patient use of medicines. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events, and circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from reports, research surveys, clinical trials studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, from other publicly available information, and from government data and similar sources. INTELLECTUAL PROPERTY C4 Therapeutics, Inc., owns various registered and unregistered trademarks and service marks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks, service marks, or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks, service marks, and trade names in this presentation are referred to without the symbols ®, SM and , but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights to these trademarks, service marks, or trade names. © 2026 C4 Therapeutics, Inc.
Advancing Differentiated TPD Medicines and Building a Sustainable Pipeline of High-value Degraders To Achieve Our Vision 3© 2026 C4 Therapeutics, Inc. STRATEGY: DEVELOP BEST-IN-CLASS AND FIRST-IN-CLASS DEGRADERS. VALIDATED PATHWAYS. LARGE MARKET OPPORTUNITIES Multiple myeloma (MM); Non-small cell lung cancer (NSCLC); Targeted Protein Degradation (TPD) Potential Best-in- Class IKZF1/3 Degrader for MM Discovery Strategy Focused on INN (Inflammation, Neuroinflammation, and Neurodegeneration) Financial Strength to Execute Establishing cemsidomide as a potential foundational therapy for the treatment of MM across multiple lines of therapy Progressing potential first-in-class degraders focused on INN diseases to build a sustainable pipeline Cash runway expected to end of 2028, beyond key value inflection points across the portfolio Vision: To become a fully integrated biopharmaceutical company Platform Collaborations Expand TPD Reach Leveraging discovery collaborations to generate non-dilutive capital and to realize our full potential of TPD
C4T is Focused on Advancing Potential Best-in-Class And First-in-Class Degraders Across Clinical Oncology Portfolio and INN Discovery Strategy © 2026 C4 Therapeutics, Inc. Advance potential best- in-class and first-in-class degraders • Enroll 2 clinical trials with cemsidomide to address 2L+ and 4L+ opportunities in MM • Establish combinability profile with cemsidomide + elranatamab1 • Optimize indication selection for multiple targets across discovery portfolio Unlock value across portfolio • Initiate and enroll Phase 3 trial of cemsidomide + BCMAxCD3 Bispecific • Present efficacy and safety data from the Phase 2 MOMENTUM trial • Potentially submit NDA for cemsidomide • Deliver 3 potential INDs from discovery pipeline in INN indications Position for regulatory success and pipeline build • Complete enrollment for Phase 2 MOMENTUM trial • Initiate additional Phase 1b trial • Present two cemsidomide data readouts: Initial ORR data from Phase 2 MOMENTUM trial Phase 1b data w/ elranatamab1 to support advancement to Phase 3 trial • Start up activities for Phase 3 cemsidomide + BCMAxCD3 Bispecific • Advance internal discovery pipeline to enable INDs 202820272026 1.Pfizer supplying elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for the Phase 1b trial; 2 Announced collaboration agreement on April 9, 2026 (https://ir.c4therapeutics.com/news-releases/news-release-details/c4- therapeutics-expands-long-term-partnership-roche-through-new) Dexamethasone (dex); Inflammation, Investigational new drug (IND); New Drug Application (NDA); Overall response rate (ORR); Inflammation, Neuroinflammation, Neurodegeneration (INN); Accelerated approval (AA); Multiple myeloma (MM); Degrader antibody conjugates (DACs) 4 Q1 2026 Key Accomplishments: First patient dosed in cemsidomide Phase 2 MOMENTUM trial First patient dosed in cemsidomide Phase 1b trial in combination with elranatamab Expanded long-term partnership with Roche through new collaboration agreement focused on discovering and developing DACs2 Received a $2 million milestone payment for designing and delivering a second degrader to Biogen for clinical development Shared plan to initiate a Phase 1b trial evaluating cemsidomide with approved multiple myeloma therapies
Focused Pipeline Advancing Clinical Oncology Degraders and a New Discovery Strategy in Inflammation, Neuroinflammation & Neurodegeneration (INN) Diseases 5© 2026 C4 Therapeutics, Inc. By year-end 2026: Optimize indication selection for multiple targets INN Inflammation, Neuroinflammation & Neurodegeneration Novel targets in pathways of: -IL-23/IL-17 -Type 1 IFN -MAPK, PI3K/AKT, NF-kB Discovery INN DISCOVERY 1. License and collaboration agreement with Betta Pharmaceuticals for development and commercialization in Greater China 2. Pfizer supplying elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for the Phase 1b trial Dexamethasone (dex) NEXT MILESTONEPHASE 3PHASE 2PHASE 1 RESEARCH & PRECLINICALINDICATIONSTARGETPROGRAM CLINICAL ONCOLOGY PORTFOLIO Q1 2027: Complete enrollment 2H 2027: Present initial ORR data 4L+ Multiple Myeloma IKZF1/3Cemsidomide 2H 2026: Provide incremental updates Mid-2027: Present Phase 1b data from all cohorts 2L+ Multiple Myeloma Non-Small Cell Lung Cancer EGFR L858RCFT89191 Phase 2 MOMENTUM trial w/ dex Phase 1b trial w/ elranatamab2
Strategic Platform Collaborations Expand Potential Reach of C4T TPD Medicines 6© 2026 C4 Therapeutics, Inc. 1. Earned and received preclinical milestones in Q1 2025 2. Delivered development candidates to Biogen in Q1 2025 and Q3 2024. In Q3 2025, the IRAK4 degrader, BIIB142, entered Phase 1 clinical development and in Q1 2025, the BTK degrader, entered Phase 1 clinical development Targeted Protein Degradation (TPD); Degrader antibody conjugates (DACs) By year-end 2026: Deliver at least one development candidate to collaboration partner 1) Evaluating targets in autoimmune diseases & oncology Advanced two programs to preclinical milestones1 2) Discovering and developing DACs for two programs against oncology targets Discovering targeted protein degraders against critical oncogenic proteins Achieved preclinical milestone from a project within the KRAS family Delivered two development candidates (IRAK4 and BTK) for non-oncology targets2 Both development candidates are now in Phase 1 clinical development Ongoing Collaborations
Cemsidomide IKZF1/3 Degrader Multiple Myeloma
Cemsidomide is Positioned for Success in Multiple Myeloma 8© 2026 C4 Therapeutics, Inc. Two ongoing trials with a third trial expected to start next year to support cemsidomide’s potential to become a foundational MM treatment Cemsidomide has a potential best-in-class profile among other IKZF1/3 degraders, including CELMoDs®, in a large and growing multiple myeloma market with a clinically and commercially de-risked MOA Despite recent approval for immune-based therapies in the MM landscape, IKZF1/3 are central drivers of MM development and progression, thus IKZF1/3 degraders will remain relevant across multiple lines and in combinations Multiple myeloma (MM) CELMoDs® is a registered trademarks of BMS
IKZF1/3 are Transcription Factors That are Central Drivers of Multiple Myeloma Development and Progression © 2026 C4 Therapeutics, Inc. Multiple myeloma (MM) IMiDs® and CELMoDs® are registered trademarks of BMS 9 Physiological Functions: • IKZF1/3 directly regulate the activity of IRF4, another transcription factor that regulates downstream immune cell differentiation Oncogenic Functions: • Multiple myeloma cells rely on IKZF1/3 and IRF4 for survival IKZF1/3 Degradation Leads to: • Downregulation of IRF4 promoting proliferation and myeloma cell death • T-cell activation • On-target neutropenia Key Roles of IKZF1/3 Common Myeloid Progenitor Cell Common Lymphoid Progenitor Cell Neutrophil Platelets B-Cell Plasma Cell Oncogenic Mutations/Aberrations Multiple Myeloma IRF4 IKZF1/3 and IRF4 IKZF1/3 Hematopoietic Stem Cell T-cell Activation Adapted from Chen and Gooding, 2022 IKZF1/3 Degrader IMiDs® ( ), CELMoDs® ( Iberdomide Mezigdomide ), and cemsidomide all degrade IKZF1/3 to drive anti-myeloma activity
The MOA of IKZF1/3 Degraders Supports Their Role Across Lines of Treatment and Combinations 10 ~11K MM patient deaths expected in the U.S. in 20263 ~40% MM patients do not survive beyond five years, despite recent treatment advances4 ~$59B Total projected MM market in U.S., Japan, EU4+UK by 20342 2/3 Line • IKZF1/3 degraders remain relevant across multiple lines of therapy • Unmet need for an IKZF1/3 degrader that is well-tolerated with compelling anti- myeloma activity CAR-T Anti-CD38 + PI + IKZF1/3 degrader + dex PI + IKZF1/3 degrader + dex Anti-CD38 mAB + IKZF1/3 degrader + dex Anti-SLAMF7 based regimens Anti-CD38 mAB + IKZF1/3 degrader + dex Anti-CD38 + PI + IKZF1/3 degrader + dex PI + IKZF1/3 degrader doublets for frail patients Anti-CD38 + PI + dex PI + IKZF1/3 degrader doublets for frail patients BCMA bispecific5 Selinexor based regimen Anti-CD38 regimen rechallenge GPRC5D bispecific = IKZF1/3 degrader regimens present across multiple lines of therapy Treatment Landscape of Approved MM Agents in 20251 4/5+ Line 1 NCCN guidelines, accessed in September 2025; 2 Datamonitor (accessed 5/1/2026) 3 American Cancer Society; 4 https://seer.cancer.gov/statfacts/html/mulmy.html (accessed June 2026). 5 Linovesltamab is only approved in 5L Multiple myeloma (MM); dexamethasone (dex) ~$25.5B Expected revenue for RRMM in U.S., Japan, EU4+UK by 20342 © 2026 C4 Therapeutics, Inc.
First-generation IKZF1/3 Degraders (IMiDs®) Have Limitations Supporting the Need for Next-generation IKZF1/3 Degraders 11© 2026 C4 Therapeutics, Inc. High to moderate renal clearance decreasing tolerability • ~50% of MM patients suffer from renal impairment1 First-gen IKZF1/3 degraders’ potency vs. Next-gen IKZF1/3 degraders’ potency (illustrative graphic) First-generation IKZF1/3 degrader limitations: 1Rana 2020 Blood Advances. 2. Tinsley S, Kurtin S, Ridgeway J Practical Management of Lenalidomide-Related Rash Clinical Lymphoma, Myeloma and Leukemia, 15, S64-S69; Dimopoulos, M., Leleu, X., Palumbo, A. et al.; Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 28, 1573–1585 (2014). https://doi.org/10.1038/leu.2014.60; 4. CELMoDs May Represent Next Wave of Immunomodulation Approaches in Multiple Myeloma | OncLive 5. Developing next generation immunomodulatory drugs and their combinations in multiple myeloma - PMC Multiple myeloma (MM); First-generation (First-gen); Next-gen (Next generation) IMiDs® is a registered trademarks of BMS Potency not optimized resulting in both modest on- target degradation, limiting anti-myeloma activity, and blockade of proliferation alone, increasing the risk of resistance mechanisms emerging4 Not as selectiveand results in off-target non hematology toxicities5 • Gastrointestinal (GI) and skin side effects are often observed2,3 Least to Most Potent IKZF1/3 Degraders Next-gen IKZF1/3 Degraders: (Iberdomide, Mezigdomide, Cemsidomide)
Phase 1 Trial of Cemsidomide + Dexamethasone Enrolled a Heavily Pre-treated Patient Population with Majority Receiving Prior CAR-T or T-cell Engager Therapy 12© 2026 C4 Therapeutics, Inc. Safety Population (N=73) Characteristics 7 (3-22)Prior therapies, median (range) 37 (51)Prior CAR-T therapy, n (%) 40 (55)Prior T-cell engager therapy, n (%) 55 (75)Prior CAR T or T-cell engager therapy, n (%) 22 (30)Prior CAR T and T-cell engager therapy, n (%) 55 (75)Prior BCMA therapy, n (%) 73 (100)Triple-class exposed*, n (%) 59 (81)Penta-drug exposed†, n (%) Heavily Pre-treated Patient Population Cemsidomide’s patient population is representative of current multi-refractory patients *Defined as exposed to ≥1 immunomodulatory agent, ≥ 1 proteasome inhibitor, and 1 anti-CD38 monoclonal antibody; †Defined as exposed to ≥2 immunomodulatory agents, ≥ 2 proteasome inhibitors, and 1 anti-CD38 monoclonal antibody Enrollment was completed in September 2025 Cemsidomide Phase 1 data cutoff as of 2/27/2026; Source: C4T data on file. Poster presentation at EHA 2026 (https://ir.c4therapeutics.com/static-files/0081f021-bc0d-4e7f-bdb9-9a01e95ed6eb)
Cemsidomide + Dexamethasone Demonstrated a Well-tolerated Profile With Minimal Dose Reductions and Discontinuations 13© 2026 C4 Therapeutics, Inc. Grade 5 (N=73) Grade 4 (N=73) Grade 3 (N=73) All Grades (N=73) Hematologic and Infection TEAEs, n (%) 026 (36)16 (22)45 (62)Neutropenia 1 (1) 0 0 1 (1) 0 0 1 (1) 0 0 0 0 1 (1) 21 (29) 11 (15) 2 (3) 0 2 (3) 0 46 (63) 13 (18) 13 (18) 1 (1) 2 (3) 1 (1) Infections Pneumonia URTI Septic Shock Sepsis PML* 01 (1)17 (23)28 (38)Anemia 08 (11)10 (14)22 (30)Leukopenia 03 (4)5 (7)14 (19)Thrombocytopenia 01 (1)7 (10)12 (16)Lymphopenia 01 (1)3 (4)4 (6)Febrile Neutropenia Neutropenia was manageable with majority of events occurring in the first two cycles3 45% of patients received G-CSF across all doses Limited grade 3/4 non-hematology side effects Minimal dose reductions • TEAEs leading to dose reductions: 5/73 (7%)1 No discontinuations related to cemsidomide • 3 TEAEs led to discontinuation, unrelated to cemsidomide2 • *Grade 4 PML considered possibly related but occurred in the setting of pre-existing chronic lymphopenia and prior exposure to immunosuppressive therapies, including therapies that have been associated with PML. Patient had recurrent seizures in the setting of a brain lesion with a negative CSF for PML. After withdrawal of care due to recurrent seizures and ultimately death, autopsy report indicated a brain lesion consistent with PML diagnosis. • 4 patients experienced grade 5 AEs (septic shock, subdural hematoma, T-Cell lymphoma and partial seizures), all deemed unrelated to cemsidomide 1Dose Reductions: A patient in the 75 µg cohort had grade 4 thrombocytopenia possibly related to cemsidomide resulting in dose reduction; A patient in the 100 µg cohort had grade 3 pneumonia; Another patient at 100 µg had grade 3 neutropenia, both AEs possibly related to cemsidomide resulting in dose reduction; a patient in the 100 µg cohort had a dose reductions after an AE of arthralgia, deemed possibly related to cemsidomide; a patient in the 100 µg cohort had two dose reductions after two events of pseudomonal bacteremia, deemed unrelated to cemsidomide. 2 3 patients discontinued due to a grade 5 AE of septic shock, grade 5 AE of T cell lymphoma, grade 5 AE of partial seizures, all deemed unrelated to cemsidomide 3 C4T data on file, presented at IMS September 2025 Treatment emergent adverse events (TEAEs) Cemsidomide Phase 1 data cutoff as of 2/27/2026; Source: C4T data on file. Poster presentation at EHA 2026 (https://ir.c4therapeutics.com/static-files/0081f021-bc0d-4e7f-bdb9-9a01e95ed6eb)
Cemsidomide + Dexamethasone Demonstrated Deep and Durable Responses Across the Highest Two Dose Levels With Some Responses Deepening Over Time © 2026 C4 Therapeutics, Inc. 14 a 15% (11) 14% (10) 20% (4) 15% (3) 16% (3) 16% (3) 35% (25) 36% (26) 25% (5) 30% (6) 21% (4) 21% (4) 14% (10) 14% (10) 15% (3) 15% (3) 11% (2) 11% (2) 26% (19) 24% (17) 40% (8) 35% (7) 37% (7#) 6% (4) 7% (5) 5% (1) 5% (1) 3% (2) 3% (2) 11% (2) 0% 25% 50% 75% 100% Data Presented Oct. 2025 Data Presented EHA 2026 Data Presented Oct. 2025 Data Presented EHA 2026 Data Presented Oct. 2025 Data Presented EHA 2026 Be st R e sp o ns e % ( N )* 26% (5) ORR 36% ORR 40% ORR 53% • At 75 µg: 1 patient who previously achieved a PR deepened to a VGPR • At 100 µg: 1 patient who previously achieved a PR deepened to a sCR; 1 patient who previously achieved a PR deepened to a VGPR • At 100 µg: Two patients who achieved a sCR and CR also achieved MRD negativity • mPFS across all doses: 3.9 months (95% CI, 3.2 – 5.6) • mDOR across all doses: 7.9 months (95% CI, 3.0 - NE) *Investigator assessed response; 1 In the Phase 1 cemsidomide + dexamethasone trial evaluated doses of 50 µg MWF, 37.5 µg MWF, 62.5 µg QD, 75 µg QD, 100µg QD; a1 patient in the 62.5 µg cohort did not have a post-baseline assessment; #2 patients in the 100 µg cohort had an unconfirmed PR in the October 2025 dataset ; bAfter the 2/27/26 data cutoff one patient went from VGPR to sCR; cAfter the 2/27/26 data cutoff one patient went from PR to VPGR Clinical benefit rate (CBR); Dexamethasone (dex); Minimal response (MR); Minimal residual disease (MRD); Objective response rate (ORR); Progressive disease (PD); Partial response (PR) ; Once daily (QD); Relapsed/refractory multiple myeloma (RRMM); Stringent complete response (sCR); Stable disease (SD); Very good partial response (VGPR); Confidence Interval (CI) a 75 µg QD (N=20) 100 µg QD (N=19)All Doses1 (N=72) For EHA 2026 data: Cemsidomide Phase 1 data cutoff as of 2/27/2026;. Poster presentation at EHA 2026 (https://ir.c4therapeutics.com/static-files/0081f021-bc0d-4e7f-bdb9-9a01e95ed6eb) For Oct. 2025 data: C4T data on file as of 9/10/2025 (0a4b569a-ab8f-4cbd-9b99-cc6a9ff19d0b) 11% (2c) 11% (2) 5% (1b) 1% (1) 3% (2) VGPR+ 10% VGPR+ 13% VGPR+ 5% VGPR+ 16% VGPR+ 26%
ORR was Consistent Across Key Subgroups in the Phase 1 Trial of Cemsidomide + Dexamethasone 15© 2026 C4 Therapeutics, Inc. Cemsidomide Phase 1 data cutoff as of 2/27/2026; Source: C4T data on file. Poster presentation at EHA 2026 (https://ir.c4therapeutics.com/static-files/0081f021-bc0d-4e7f-bdb9-9a01e95ed6eb) Overall response rate (ORR); Recommended Phase 2 Dose (RP2D) ORR across key subgroups: ORR % (95% CI)Responders/ PatientsAll Doses 37.0% (24.3, 51.3)20/54Prior CAR-T or T-cell engager therapy 33.3% (21.1, 47.5)18/54Prior BCMA 33.3% (20.4, 48.4)16/48> 5 Prior Lines of Therapy ORR acros key subgroups: ORR % (95% CI)Responders/ PatientsAt 100 µg (RP2D) 52.9% (27.8, 77.0)9/17Prior CAR-T or T-cell engager therapy 46.6 % (21.3, 73.4)7/15Prior BCMA 46.7% (21.3, 73.4)7/15> 5 Prior Lines of Therapy
Cemsidomide Has the Potential to Be a Foundational Treatment Across Multiple Lines of Multiple Myeloma 16© 2026 C4 Therapeutics, Inc. Late-line Opportunity Combination with dexamethasone R A T I O N A L E • Only next-generation IKZF1/3 degrader with a label-enabling development strategy for the 4L+ • Unmet need for an all-oral treatment regimen that is both well-tolerated and efficacious for patients who have exhausted all options • Near-term value • Data from the Phase 1 trial of cemsidomide + dexamethasone demonstrated a potential best-in- class profile5 Novel Combination Combination with BCMAxCD3 Bispecific R A T I O N A L E • For use in earlier lines • Goal is to establish cemsidomide as an IKZF1/3 degrader of choice for novel combinations • Complementary MOA via T-cell activation with potential to drive potent anti-myeloma effect • Data from MagnetisMM-30 trial1 demonstrates proof- of-concept for combination with opportunity to improve depth of response IMiD® Replacement Across Lines Combination with a PI or CD38 antibody R A T I O N A L E • Opportunity to improve upon first-generation IKZF1/3 degraders • Establish dose of cemsidomide for potential standard of care combination approaches • Upcoming data from the EXCALIBER RRMM trial2 and SUCCESSOR-1 trial4 GOAL: Develop a potential best-in-class IKZF1/3 degrader to become partner of choice for MM treatment 1Clinical trial evaluating elranatamab in combination with iberdomide in RRMM; 2.EXCALIBER RRMM trial is a Phase 3 trial comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone 3 . Pfizer supplying elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for the Phase 1b trial. 4. SUCCESSOR-1 is a Phase 3 trial evaluating mezigdomide, bortezomib, dexamethasone versus pomalyst, bortezomib, dexamethasone IMiDs® are registered trademarks of BMS 5. Cemsidomide Phase 1 data cutoff as of 2/27/2026; Source: C4T data on file. Poster presentation at EHA 2026 (https://ir.c4therapeutics.com/static-files/0081f021-bc0d-4e7f-bdb9-9a01e95ed6eb) S T A T U S Enrolling Phase 2 MOMENTUM Trial • Cemsidomide + dexamethasone S T A T U S Enrolling Phase 1b Trial • Cemsidomide + dexamethasone + elranatamab3 S T A T U S Initiation of Phase 1b Trial w/ Two Arms Expected in 1H 2027 • Cemsidomide + dexamethasone + PI • Cemsidomide + dexamethasone + CD38 antibody GOAL: Develop a potential be t-in-class IKZF1/3 degrader to become partner of choice for MM treatment 3 strategic paths to capture multi-billion dollar opportunities
Phase 2 MOMENTUM Trial of Cemsidomide + Dexamethasone in 4L+ MM Now Enrolling Patients © 2026 C4 Therapeutics, Inc. Dexamethasone (dex); Overall response rate (ORR); Fourth line (4L); Recommended Phase 2 dose (RP2D); Overall response (ORR); International Myeloma Working Group (IMWG); Once daily (QD) 17 Endpoints: ORR per IMWG response criteria assessed by independent review committee • 20% increase over a background rate of 20% RP2D: 100 µg Schedule: QD 14/14 Potential for accelerated approval PHASE 2 MOMENTUM TRIAL DESIGN: 2H 2027: Phase 2 initial ORR data Phase 2 MOMENTUM Cemsidomide + dex (single arm) 4L+ N = ~100 Dose: 100 µg QD Enrollment Expected to Complete in Q1 2027
BCMA-binding arm CD3-binding arm Myeloma cell T cell CD3 Enhanced myeloma cell killing with elranatamab + cemsidomide Elranatamab BCMA Elranatamab + cemsidomide + dexamethasone may provide additional benefit to patients with RRMM based on the complementary mechanisms of action CRN Based on Complementary Mechanisms of Action, Cemsidomide in Combination with Elranatamab Has Potential to Provide Additional Benefit to Patients 18© 2026 C4 Therapeutics, Inc. Elranatamab is a BCMAxCD3 Bispecific approved as a monotherapy for patients with RRMM who have received ≥1 IMiD®, ≥1 PI, and ≥1 anti-CD38 mAb1-2 Cemsidomide is an oral IKZF1/3 degrader, advancing through clinical development, with a potential best-in-class profile: • Demonstrated t-cell activation across clinically relevant doses as a monotherapy and in combination w/ dexamethasone3 1Elrexfio (elranatamab-bcmm). Prescribing information. Pfizer Inc; 2025.; 2Elrexfio (elranatamab-bcmm). Summary of product characteristics. Pfizer Europe MA EEIG; 2024; 3 C4T data on file: https://ir.c4therapeutics.com/static-files/39670c4f- 0806-41b6-8813-ef7adcf04207 ; https://ir.c4therapeutics.com/static-files/ec59b02e-3074-484d-ad88-e81831bf37ed B-cell maturation antigen (BCMA); Immunomodulatory drug (IMiD); Monoclonal antibody (mAb); Proteasome inhibitor (PI); Relapsed or refractory multiple myeloma (RRMM); Cereblon (CRBN) IMiDs® are registered trademarks of BMS Cytokines, perforin, granzymes Cemsidomide IKZF1/3 Ubiquitin ↓myeloma cell survival ↓myeloma cell proliferation ↑immunomodulation T cells, activated by CD3 binding, release cytokines and perforin/granzymes, resulting in myeloma cell lysis
0% 20% 40% 60% 80% 100% ORR Range >CR Range Early IKZF1/3 Degrader + BiTE Data Provide Proof of Concept for Cemsidomide with Opportunity For Improvement © 2026 C4 Therapeutics, Inc. Currently CAR-Ts demonstrate higher ORR and >CR than BiTEs alone1,2 Early data from IKZF1/3 degrader + BiTE combo support POC for similar anti- myeloma activity to CAR-Ts with better overall profile, but opportunity to improve depth of response Cemsidomide is well-positioned to provide further differentiation to BiTE combination Sources: 1Packaging Insert for each product (carvykti – accessed 8/26/25) 2. Labels from tecvayli; elrexflo; lynozyfic - accessed 2/27/26 - the data is not a head-to-head trial; 32025 ASH ORR data at each dose level from Phase 1b MagnetismMM-30 trial evaluating iberdomide + elranatamab 4 Pfizer supplying elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for the Phase 1b trial Bispecifc T-cell engager (BiTE); Overall response rate (ORR); Complete response (CR); Combination (combo); Minimal residual disease (MRD) CEMSIDOMIDE DEVELOPMENT RATIONALE IN 2L+ IN COMBO WITH A BITE Opportunity to improve BiTE response rate including depth of response 19 • Combination is safe • Early evidence of anti-myeloma activity Differentiated safety profile Compelling anti-myeloma activity across the highest 3 doses T-cell activation observed across all cemsidomide dose levels Phase 1b trial with elranatamab4 will evaluate MRD negative responses 74% ~58% - 70% CAR-T1 BiTE2 BiTE + IKZF1/33 BiTE + IKZF1/33 CAR-T1 BiTE2 ~74%>90% ~26% - 45% ~44%~85%
Phase 1b Trial is Evaluating Safety and Tolerability of Cemsidomide in Combination With Elranatamab, With Data From All Cohorts Expected in Mid-2027 © 2026 C4 Therapeutics, Inc. 1 Pfizer will supply elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for its upcoming Phase 1b trial Dexamethasone (dex); Once daily (QD); Once weekly (QW) PHASE 1b TRIAL DESIGN: Primary Objectives: Characterize the safety and tolerability of cemsidomide in combination with elranatamab Dosing Regimen: • Cemsidomide: QD 14/14 • Dexamethasone: QW through cycle 4 • Elranatamab 1 Key Differentiators: • Evaluated with dex, which may help manage neutropenic complications • Focused on evaluating MRD negativity rates to demonstrate depth of response 20 Cemsidomide Dose Level: 75 µg + Elranatamab If 75 µg is declared safe, potential to simultaneously evaluate 50 µg and 100 µg Cemsidomide Dose Level: 50 µg + Elranatamab Cemsidomide Dose Level: 100 µg + Elranatamab Potential to expand at each dose level once combination is declared safe Trial Initiated in Q1 2026; Enrollment Ongoing 2026: Provide incremental updates throughout Phase 1b dose escalation Elranatamab step-up dosing without cemsidomide
Discovery Inflammation, Neuroinflammation, & Neurodegeneration (INN)
New Discovery Strategy Focused on Inflammation, Neuroinflammation & Neurodegeneration (INN) with First-in-Class Potential in Clinically Validated Pathways Uniquely Suited for TPD 22© 2026 C4 Therapeutics, Inc. Targeted Protein Degradation (TPD); Central nervous system (CNS) Leveraging C4T’s success Maximizing value through target selection Deliver degraders with first-in-class potential that are CNS penetrant C4T HAS CONSISTENTLY DEVELOPED ORALLY BIOAVAILABLE HIGHLY CATALYTIC HETEROBIVALENT DEGRADERS THAT… • Penetrate the blood brain barrier to achieve high central nervous system exposures and compelling efficacy in central nervous system models • Control target protein levels through finely-tuned degrader kinetics TARGET-TO-DISEASE LINK: • Selecting targets that modulate clinically validated pathways in inflammation, neuroinflammation, and neurodegeneration (INN) to enhance efficacy • Focusing on early clinical validation with opportunity to grow value through indication expansion STRONG DEGRADER RATIONALE: • Strong competitive positioning • Clear and compelling advantage for a degrader over an inhibitor EXPANDED CAPABILITIES: • Extended capabilities to identify molecular glue degraders for targets with and without G- and RT-loops by utilizing DNA-encoded library (DEL) technology
Focused on Inflammation, Neuroinflammation & Neurodegeneration (INN) to Address High Unmet Needs in a Large Patient Population with a Clear TPD Advantage © 2026 C4 Therapeutics, Inc. Central nervous system (CNS), Pharmacodynamic (PD); Targeted Protein Degradation (TPD); Mechanism of action (MOA) 1Based on preclinical evidence and working hypothesis 23 Deploying TPD where the MOA is uniquely positioned to have an advantage over inhibitors to help benefit patients in a large market Degraders have the potential to outperform inhibitors in efficacy and safety in CNS diseases1 Fast path to clinical proof-of-concept, including early validation based on PD markers in healthy volunteers Normalize elevated protein levels without the need for complete elimination of the target Large market opportunities with high unmet medical needs
Potential for Degraders To Be the Optimal Therapeutic Modality for CNS Diseases Over Inhibitors 24 Theoretical Inhibitor and Degrader Brain PK Curves for Molecules With Similar Efficacy* (Illustrative graphic) *For target proteins with a long resynthesis rate Lower exposure levels for highly catalytic degraders are required for efficacy versus inhibitors to achieve efficacious results in CNS diseases Pharmacokinetics of inhibitors is associated with high Cmax driving toxicities vs. degraders have consistent and sustained levels resulting in lower toxicity issues Sources: Drug Discov Today. 2019 May;24(5):1067-1073. doi: 10.1016/j.drudis.2019.01.015; Pharm Res. 2022 Jul;39(7):1321-1341. doi: 10.1007/s11095-022-03246-6 Central nervous system (CNS); Pharmacokinetic (PK) © 2026 C4 Therapeutics, Inc.
Pursuing Targets in Validated Pathways With Application to a Broad Set of Indications © 2026 C4 Therapeutics, Inc. *Highlights indications that are central nervous system diseases Image 1 Zheng M-Y, Luo L-Z Int. J. Mol. Sci. 2025; Image 2:Lukhele S, et al. Semin Immunol 2019; Image 3Liu T, et al, Sig. Transduct. Target. Ther. 2017 Alzheimer’s Disease* Psoriasis Multiple Sclerosis* Down Syndrome* Parkinson’s Disease* Rheumatoid Arthritis Multiple Myeloma Lupus Nephritis Systemic Lupus Erythematosus Inflammatory Bowel Disease Asthma Autosomal Dominant Polycystic Kidney Disease Chronic Kidney Disease Metabolic Dysfunction Associated Steatohepatitis Idiopathic Pulmonary Fibrosis POTENTIAL INDICATIONS IL-23/IL-17 Pathway Type 1 IFN Pathway MAPK, PI3K/AKT, NF-kB Pathways 25
C4T is Focused on Advancing Potential Best-in-Class And First-in-Class Degraders Across Clinical Oncology Portfolio and INN Discovery Strategy © 2026 C4 Therapeutics, Inc. Advance potential best-in-class and first-in-class degraders • Enroll 2 clinical trials with cemsidomide to address 2L+ and 4L+ opportunities in MM • Establish combinability profile with cemsidomide + elranatamab1 • Optimize indication selection for multiple targets across discovery portfolio Unlock value across portfolio • Initiate and enroll Phase 3 trial of cemsidomide + BCMAxCD3 Bispecific • Present efficacy and safety data from the Phase 2 MOMENTUM trial • Potentially submit NDA for cemsidomide • Deliver 3 potential INDs from discovery pipeline in INN indications Position for regulatory success and pipeline build • Complete enrollment for Phase 2 MOMENTUM trial • Initiate additional Phase 1b Trial • Present two cemsidomide data readouts: Initial ORR data from Phase 2 MOMENTUM trial Phase 1b data w/ elranatamab1 to support advancement to Phase 3 trial • Start up activities for Phase 3 cemsidomide + BCMAxCD3 Bispecific • Advance internal discovery pipeline to enable INDs 202820272026 1 Pfizer supplying elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody, to C4T for the Phase 1b trial Dexamethasone (dex); Inflammation, Investigational new drug (IND); New Drug Application (NDA); Overall response rate (ORR); Inflammation, Neuroinflammation, Neurodegeneration (INN); Accelerated approval (AA); Multiple myeloma; Degrader antibody conjugates (DACs) 26
• Cemsidomide is a novel, highly potent, cereblon-based, IKZF1/3 MonoDAC® degrader, having a similar mechanism of action as BMS’s IMiD® or CELMoD® degraders for MM • Cemsidomide displays catalytic activity enabling rapid and deep target degradation with high binding affinity to overcome resistance due to low cereblon levels • Cemsidomide binds to cereblon to facilitate the recruitment and ubiquitination of IKZF1/3 leading to the proteasomal degradation of both proteins (Figure 1) • IKZF1/3 degradation induces multiple myeloma cell death, activation of fully differentiated T-cells which prevents T-cell exhaustion and promotes secretion of key immune stimulating cytokines1 Sagar Lonial, MD1, Andrew J. Yee, MD2, Paul G. Richardson, MD3, Sikander Ailawadhi, MD4, Saurabh Chhabra, M.B.B.S5, Wilson Gonsalves, MD6, Jesus G. Berdeja, MD7, Shambavi Richard, MD8, Jeffrey V. Matous, MD9, Urvi A. Shah, MD10, Mark A. Schroeder, MD11, Nisha Joseph, MD1, Sumedha Javalikar, MPH12, Amro Ali, PharmD12, Leah Leahy, BS12, Uma Chandrasekaran, PhD12, Riadh Lobbardi, PhD12, Rong Chu, PhD12, Eunju Hurh, PhD12, Leonard Reyno, MD12, and Binod Dhakal, MD13 1Winship Cancer Institute, Emory University, Atlanta, GA 2Massachusetts General Hospital Cancer Center, Boston, MA; 3Dana-Farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA; 4Division of Hematology, Mayo Clinic, Jacksonville, FL; 5Mayo Clinic Arizona, Phoenix, AZ; 6Mayo Clinic Rochester, Saint Paul, MN; 7Tennessee Oncology, Nashville, TN; 8Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY; 9Sarah Cannon Research Institute, Colorado Blood Cancer Institute, Denver, CO; 10Memorial Sloan Kettering Cancer Center, New York, NY; 11Washington University School of Medicine, St. Louis, MO; 12C4 Therapeutics, Inc., Watertown, MA; 13Medical College of Wisconsin, Milwaukee, Wisconsin Methods Conclusions ResultsIntroduction Updated Results of a Phase 1 First-in-Human Study of Cemsidomide, a Novel MonoDAC® Degrader, with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) IKZF1/3 Degradation Induces: •Multiple Myeloma cell death • Immune stimulation ‒ Activates fully differentiated T- cells, preventing T-cell exhaustion ‒ Promotes secretion of key immune stimulating cytokines (e.g., IL-2) •On-target neutropenia – Disrupts hematopoietic stem cell differentiation CFT7455-1101 Study Design3 •Open-label, multicenter, phase 1/2 clinical trial with dose escalation and expansion phases (NCT04756726)* •Dose escalation phase, beginning with a starting oral dose of 50 µg MWF 14 days on/14 days off, following a Bayesian logistic regression model until determination of the MTD and/or RP2D ‒ Escalation cohorts enrolled 3-6 patients, once dose was declared safe by SRC, additional patients were eligible to enroll at the dose deemed safe ▪ G-CSF and transfusions were not allowed in cycle 1 for dose escalation subjects ▪ Once a dose was declared safe, additional patients at each dose level were allowed G-CSF use at any timepoint *CFT7455 administered as 14 days on/14 days off in a 28-day cycle; Dex was dosed on days 1, 8, 15, and 22 at doses of 40 mg orally for patients ≤75 years old and 20 mg orally for patients >75 years old; 1DLT in the 62.5 µg QD was due to grade 4 neutropenia lasting >7 days; 2 Three patients in the 100 µg QD escalation had 5 DLT events (G4 neutropenia, G3 pneumonia in 2 subjects, G3 ALT increase, G3 febrile neutropenia) Patients Table 2: Prior TherapiesTable 1: Baseline Characteristics • At the data cutoff date (February 27, 2026), 73 patients had received cemsidomide + dexamethasone • Baseline characteristics are shown in Table 1, and prior therapies are shown in Table 2 ‒ Patients were heavily pre-treated, having received a median of 7 prior lines of therapy (range 3-22) ‒ 75% of patients had received a CAR-T or TCE and 75% had received a prior BCMA therapy *Defined as exposed to ≥1 immunomodulatory agent, ≥ 1 proteasome inhibitor, and 1 anti-CD38 monoclonal antibody; †Defined as exposed to ≥2 immunomodulatory agents, ≥ 2 proteasome inhibitors, and 1 anti-CD38 monoclonal antibody Table 3: Treatment Disposition *2 patients discontinued due to an AE of septic shock and an AE of partial seizures (unrelated to cemsidomide) #Death in a 62.5 µg cohort patient was due to subdural hematoma (related to a fall), unrelated to cemsidomide; death in a 100 µg cohort patient was due to T cell lymphoma (unrelated to cemsidomide); †A patient in the 50 µg MWF cohort was transferred to hospice, did not meet IMWG definition of progressive disease • Treatment disposition is shown on Table 3 with treatment ongoing for 7 patients (10%) • The primary reason for discontinuation was progressive disease (51/66) •Median time on treatment was 3.4 months Safety Table 4: Overall Treatment Emergent Adverse Events *3 patients discontinued due to a grade 5 AE of septic shock, grade 5 AE of T cell lymphoma, grade 5 AE of partial seizures, all deemed unrelated to cemsidomide #A patient in the 75 µg cohort had grade 4 thrombocytopenia possibly related to cemsidomide resulting in dose reduction; §A patient in the 100 µg cohort had grade 3 pneumonia and another patient at 100µg had grade 3 neutropenia, both AEs possibly related to cemsidomide resulting in dose reduction, a patient in the 100 µg cohort had a dose reductions after an AE of arthralgia, deemed possibly related to cemsidomide, a patient in the 100 µg cohort had two dose reductions after two events of pseudomonal bacteremia, deemed unrelated to cemsidomide. Table 5: Treatment Emergent Adverse Events by Grade Anti-Myeloma Activity Figure 3: Best Overall Response Rate Cemsidomide + Dex* Figure 5: Best % Change in dFLC from Baseline Multiple Myeloma Patients w/ Elevated Light Chain Disease (N=64)* • ORR at the highest dose level of cemsidomide (100 µg) was 53% with a clinical benefit rate of 63% (Figure 3) ‒ MRD negativity achieved in 2 patients who achieved a sCR and CR at the highest dose level of cemsidomide (100 µg) • ORR is consistent across subgroups irrespective of prior therapies (Table 6) • Median PFS across all dose levels was 3.9 months (95% CI, 3.2‒5.6) • Median DOR across all dose levels was 7.9 months (95% CI, 3.0‒NE) • Figure 5 represents the greatest dFLC reduction from baseline ‒ Cemsidomide + Dex induced a ≥ 50% decrease in dFLC in 50% (32/64) of patients ‒ Cemsidomide demonstrated anti-myeloma activity across a broad range of doses •Cemsidomide 14/14 plus Dex demonstrated durable anti-myeloma activity at increasing dose levels in a heavily pretreated patient population – A 53% ORR was observed at the highest dose of 100 µg QD, with a 36% ORR observed across all dose levels – 100 µg 14/14 QD was established as the RP2D and MTD – Responses were durable and continued to deepen over time at the 75 µg and 100 µg dose levels –ORR was consistent across subgroups, with patients receiving prior CAR-T or TCE having a 53% ORR at the RP2D •Cemsidomide 14/14 plus Dex was well tolerated across dose levels ‒ TEAEs were manageable with minimal treatment discontinuations or reductions •Cemsidomide data strongly support further development across multiple lines of treatment and in combination with other anti-myeloma agents, including PIs, CD-38 mAB, ADCs, and TCEs •Based on these results, cemsidomide 14/14 plus Dex is currently being assessed in the phase 2 MOMENTUM study in the 4L+ patient population and in a phase 1b study in combination with elranatamab (BCMA TCE) • 4 DLTs: 1 patient at 62.5 µg had grade 4 neutropenia >7 days; 3 patients at 100 µg had 5 DLT events (grade 4 neutropenia >7 days, grade 3 ALT increase, grade 3 febrile neutropenia, grade 3 pneumonia in 2 subjects) • No patient had a related TEAE leading to cemsidomide discontinuation • 4 patients experienced grade 5 AEs (septic shock, subdural hematoma, T-Cell lymphoma and partial seizures), all deemed unrelated to cemsidomide • G-CSF support was not allowed during cycle 1 for patients in dose escalation cohorts • 42/73 (58%) of patients experienced grade 3/4 neutropenia, an anticipated on-target effect of IKZF1/3 degradation ‒ Neutropenia was manageable with treatment interruptions and G-CSF use when permitted ‒ Across all doses, 45% (33/73) of patients received G-CSF *Only includes treated subjects who meet both criterion (A) and (B): (A) baseline kappa free light chain value >19.4 mg/L or baseline lambda free light chain value >26.3 mg/L; (B) ratio of baseline free light chain kappa over baseline free light chain value lambda >4:1 or <1:2. Abbreviations AE, adverse event; ALT, alanine aminotransferase; BCMA, B-cell maturation antigen; BMS, Bristol Myers Squibb; CAR-T, chimeric antigen receptor-T cell therapy; CBR, clinical benefit rate (≥MR); CD38, cluster of differentiation 38; CI, confidence interval; CR, complete response; CRBN, cereblon; CSF, cerebrospinal fluid; CUL4, cullin 4; DDB1, damage-specific DNA binding protein 1; Dex, dexamethasone; dFLC, difference between involved and uninvolved free light chains; DLT, dose-limiting toxicity; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; EMD, extramedullary disease; G-CSF, granulocyte colony-stimulating factor; IKZF1, Ikaros zinc finger protein 1; IKZF3, Ikaros zinc finger protein 3; IL-2, interleukin 2; IMWG, International Myeloma Working Group; mAb, monoclonal antibody; MM, multiple myeloma; MR, minimal response; MRD, minimal residual disease; MTD, maximum tolerated dose; MWF, Monday Wednesday Friday; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PI, proteasome inhibitor; PK, pharmacokinetics; PML, progressive multifocal leukoencephalopathy; PR, partial response; QD, daily; R-ISS, revised international staging system; R/R, relapsed/refractory; RBX1, ring-box 1; RP2D, recommended Phase 2 dose; RRMM, relapsed/refractory multiple myeloma; sCR, stringent complete response; SD, stable disease; SOC, standard of care; SRC, safety review committee; TCE, T-cell engager; TEAEs, treatment emergent adverse events; TESAEs, treatment emergent serious adverse events; URTI, upper respiratory tract infection; VGPR, very good partial response; 14/14, 14 days on/14 days off References 1. Dhakal B, et al. Clinical Lymphoma, Myeloma & Leukemia, Vol. 25, No. S2, S35, 2025 2. Henderson J, et al. Cancer Res (2022) 82 (12_Supplement): ND13 3. NCT07284758. www.clinicaltrials.gov. Accessed April 30, 2026 Acknowledgments We would like to thank the site support staff, study sponsor, and collaborators, as well as participating patients and their families for their contributions to the study. This study is sponsored by C4 Therapeutics, Inc. All authors contributed to and approved the presentation Cemsidomide DDB1 E3 Ubiquitin Ligase Complex CRBN RBX1 E2 IKZF1, IKZF3 degradation Death of myeloma cells IKZF1IKZF1 IKZF3IKZF3 Ub CUL4 KEY INCLUSION CRITERIA • Adults with MM, R/R to at least 3 prior lines of therapy that have included lenalidomide, pomalidomide, a proteasome inhibitor, a glucocorticoid, and an anti-CD38 monoclonal antibody • Nonresponsive to or progressed within 60 days of prior therapy • Creatinine clearance ≥40 mL/min • ECOG ≤2 Phase 1 Study Endpoints • Primary: assess safety, tolerability and define the RP2D/MTD • Secondary: assess PK, PD, and preliminary anti-tumor activity 100 µg QD Escalation n=10 3 DLT2 75 µg QD Escalation n=4 62.5 µg QD Escalation n=6 1 DLT1 37.5 µg QD Escalation n=4 50 µg MWF Escalation n=5 Figure 2: Phase 1 Dose Escalation Cemsidomide 14/14 + Dex* 50 µg MWF Expansion n=1 37.5 µg QD Expansion n=8 62.5 µg QD Expansion n=10 75 µg QD Expansion n=16 100 µg QD Expansion n=9 Figure 1: Mechanism of Action of Cemsidomide2 Characteristics Safety Population (N=73) Age, median (range) 67 (39-90 years) Male, n (%) 43 (59) Time since initial diagnosis, median (range) 7 (2-22 years) ECOG performance status, n (%) 0 1 2 18 (25) 52 (71) 3 (4) Asian Black or African American, n (%) White, n (%) Other, n (%) 1 (1) 15 (21) 50 (69) 7 (10) Revised ISS at screening, n (%) Stage 1 Stage 2 Stage 3 Missing 24 (33) 31 (43) 9 (12) 9 (12) Presence of EMD, n (%) 23 (32) Characteristics Safety Population (N=73) Prior therapies, median (range) 3L, n (%) 4L, n (%) ≥ 5L, n (%) 7 (3-22) 3 (4) 11 (15) 59 (81) Prior stem cell transplant, n (%) 45 (62) Prior lenalidomide, n (%) 73 (100) Prior pomalidomide, n (%) 72 (99) Prior anti-CD38 mAb, n (%) 73 (100) Prior CAR-T therapy, n (%) 37 (51) Prior T-cell engager therapy, n (%) 40 (55) Prior CAR T or T-cell engager therapy, n (%) 55 (75) Prior CAR T and T-cell engager therapy, n (%) 22 (30) Prior BCMA therapy, n (%) 55 (75) Prior GPRC5D therapy, n (%) 35 (48) Triple-class exposed*, n (%) 73 (100) Penta-drug exposed†, n (%) 59 (81) Patient Disposition, n (%) Safety Population (N=73) Ongoing 7 (10) Discontinued Progressive disease Withdrawal of consent Adverse event Death Physician Decision Other 66 (90) 51 (70) 8 (11) 2 (3)* 2 (3)# 2 (3) 1 (1)† Adverse Events, n (%) 50 µg MWF (N=6) 37.5 µg QD (N=12) 62.5 µg QD (N=16) 75 µg QD (N=20) 100 µg QD (N=19) Total (N=73) TEAEs 6 (100) 12 (100) 16 (100) 20 (100) 19 (100) 73 (100) TEAEs possibly related to cemsidomide 3 (50) 11 (92) 12 (75) 14 (70) 16 (84) 56 (77) TESAEs 3 (50) 6 (50) 7 (44) 7 (35) 9 (47) 32 (44) TESAEs possibly related to cemsidomide 0 4 (33) 3 (19) 5 (25) 4 (21) 16 (22) Any grade ≥3 TEAEs 5 (83) 8 (67) 12 (75) 18 (90) 16 (84) 59 (81) Any grade ≥3 TEAEs possibly related to cemsidomide 3 (50) 8 (67) 9 (56) 12 (60) 13 (68) 45 (62) TEAEs leading to discontinuation 0 0 0 1 (5) 2 (11) 3 (4)* TEAEs leading to reduction 0 0 0 1 (5)# 4 (21)§ 5 (7) 0 Hematologic and Infection TEAEs, n (%) All Grades (N=73) Grade 3 (N=73) Grade 4 (N=73) Grade 5 (N=73) Neutropenia 45 (62) 16 (22) 26 (36) 0 Infections Pneumonia URTI Septic Shock Sepsis PML* 46 (63) 13 (18) 13 (18) 1 (1) 2 (3) 1 (1) 21 (29) 11 (15) 2 (3) 0 2 (3) 0 1 (1) 0 0 0 0 1 (1) 1 (1) 0 0 1 (1) 0 0 Anemia 28 (38) 17 (23) 1 (1) 0 Leukopenia 22 (30) 10 (14) 8 (11) 0 Thrombocytopenia 14 (19) 5 (7) 3 (4) 0 Lymphopenia 12 (16) 7 (10) 1 (1) 0 Febrile Neutropenia 4 (6) 3 (4) 1 (1) 0 *Grade 4 PML considered possibly related but occurred in the setting of pre-existing chronic lymphopenia and prior exposure to immunosuppressive therapies, including therapies that have been associated with PML. Patient had recurrent seizures in the setting of a brain lesion with a negative CSF for PML. After withdrawal of care due to recurrent seizures and ultimately death, autopsy report indicated a brain lesion consistent with PML diagnosis. TEAEs (>20%) and Events of Interest, n (%) All Grades (N=73) Grade 3 (N=73) Grade 4 (N=73) Grade 5 (N=73) Fatigue 29 (40) 0 0 0 Diarrhea 26 (36) 1 (1) 0 0 Cough 21 (29) 1 (1) 0 0 Insomnia 20 (27) 1 (1) 0 0 Constipation 19 (26) 0 0 0 Pyrexia 19 (26) 0 0 0 Nausea 18 (25) 0 0 0 Arthralgia 18 (25) 0 0 0 Dyspnea 17 (23) 2 (3) 0 0 Hypertension 17 (23) 5 (7) 1 (1) 0 14% (10) 7% (1) 15% (3) 16% (3) 36% (26) 47% (7) 30% (6) 21% (4) 14% (10) 20% (3) 15% (3) 11% (2) 24% (17) 20% (3) 35% (7) 26% (5) 7% (5) 7% (1) 5% (1) 11% (2c) 3% (2) 11% (2) 3% (2) 5% (1b) 0% 25% 50% 75% 100% TOTAL (N=72) 62.5 µg QD (N=15) 75 µg QD (N=20) 100 µg QD (N=19) B e st R e sp o n se % ( N ) CBR 47% ORR 27% ORR 40%ORR 36% CBR 50% a CBR 55% ORR 53% 0 CBR 63% § a a1 patient in the 62.5µg cohort did not have a post-baseline assessment; bPatient went from VGPR to sCR after data cut. cPatient went from PR to VGPR after data cut. Response/Subjects ORR % (95% CI) Prior CAR-T or TCE All doses 20/54 37.0% (24.3, 51.3) 100 µg (RP2D) 9/17 52.9% (27.8, 77.0) Prior BCMA All doses 18/54 33.3% (21.1, 47.5) 100 µg (RP2D) 7/15 46.6 % (21.3, 73.4) > 5 Prior Lines of Therapy All doses 16/48 33.3% (20.4, 48.4) 100 µg (RP2D) 7/15 46.7% (21.3, 73.4) Table 6 : ORR Subgroups (All Dose Levels and 100 µg dose) a b c d *Investigator assessed response aPatient at 75µg discontinued due to grade 5 AE of septic shock, deemed unrelated to cemsidomide; bPatient at 100 ug discontinued due to grade 5 recurrent seizures, deemed unrelated to cemsidomide; CPatient went from VGPR to sCR after data cut; dPatient went from PR to VGPR after data cut. European Society of Hematology 2026 Figure 4: Best Response and Exposure (≥PR)*
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well Tolerated With Minimal Discontinuations and Dose Reductions Related to Safety or Tolerability Data Further Support Development Strategy Across Lines of Therapy and in Combination With Approved Therapies, Positioning Cemsidomide as a Potential Foundational Therapy for Relapsed/Refractory Multiple Myeloma WATERTOWN, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, will present further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM) in a poster presentation at the European Hematology Association (EHA) 2026 Congress on Friday, June 12, 2026 at 6:45 pm CEST / 12:45 pm ET. The analysis is consistent with previous data disclosed from the Phase 1 clinical trial and highlights cemsidomide's anti-myeloma activity and differentiated safety profile, further supporting its development as a potential best-in-class IKF1/3 degrader. The poster will be presented by Sagar Lonial, M.D., FACP, FASCO, chief medical officer at the Winship Cancer Institute at Emory University, and an investigator in the cemsidomide clinical trials. “Despite advances in multiple myeloma therapies, IKZF1/3 degradation remains a foundational treatment strategy across lines of therapy because it is the only approach that addresses the underlying biology of the disease and has the built-in ability to stimulate the immune function, becoming a natural partner for immune therapies. Next-generation IKZF1/3 degraders are expected to help advance treatment regimens for this persistent disease, given data demonstrating their efficacy and tolerability,” said Dr. Lonial. “The clinical activity and safety profile of cemsidomide are highly encouraging for patients with relapsed/refractory multiple myeloma as they continue to seek disease-altering treatment options. The data from the ongoing Phase 1 study support the continued development of cemsidomide for patients with relapsed/refractory multiple myeloma who may benefit from IKZF1/3 degradation.”
“The totality of cemsidomide data, particularly data showing that patients have experienced a deepening response over time, continue to demonstrate its potential to deliver a tolerable therapy that can provide sustained benefit for patients who have progressed through other treatment options,” said Len Reyno, M.D., chief medical officer of C4 Therapeutics. “We remain focused on advancing our clinical development strategy to capitalize upon cemsidomide’s differentiated profile in hopes patients at various stages of their treatment journey may be able to benefit from this important investigational therapeutic regimen.” The poster presentation includes data on 73 patients with a data cutoff of February 27, 2026. Patients were heavily pretreated, receiving a median of seven prior lines of therapy. Fifty-five patients (75%) received prior BCMA therapy, and 55 patients (75%) received prior CAR-T or T- cell engager therapy (TCE). At the RP2D and maximum tolerated dose (100 µg,) cemsidomide achieved a 53% overall response rate (ORR). At the 75 µg dose level, cemsidomide achieved a 40% ORR. Across all doses evaluated, cemsidomide achieved a 36% ORR. Key new data include: • Responses deepened over time across the cemsidomide 75 µg and 100 µg dose levels: o At 75 µg, one patient whose best response was previously a partial response (PR) deepened to a very good partial response (VGPR). o At 100 µg, several patients achieved a deeper response: ▪ One patient whose best response was previously a PR deepened to a stringent complete response (sCR) ▪ One patient whose best response was previously a PR deepened to a VGPR o Minimal residual disease (MRD) negativity was achieved in two patients who achieved a sCR and complete response (CR) at 100 µg. • ORR was consistent across key subgroups: ORR % (95% confidence interval (CI)) All Doses Prior CAR-T or TCE 37% (24, 51) Prior BCMA 33% (21, 48) Prior Lines of Therapy > 5 Lines 33% (20, 48) 100 µg (RP2D) Prior CAR-T or TCE 53% (28, 77) Prior BCMA 47% (21, 73) Prior Lines of Therapy > 5 Lines 47% (21, 73) • Durable responses were observed across all dose levels: o Patients experienced a median duration of response of 7.9 months (95% CI, 3.0 – non-evaluable). o Seven patients remain on treatment currently.
Cemsidomide in combination with dexamethasone was generally well tolerated. Incidences of on-target neutropenia remained manageable; 42 patients (58%) experienced Grade 3/4 neutropenia. All treatment emergent adverse events were manageable with no discontinuations deemed related to cemsidomide and minimal dose reductions (five patients; 7%). UPCOMING INVESTOR EVENTS • June 18, 2026 at 9 am ET: C4T will host an educational webinar with Nisha Joseph, M.D., associate professor at the Winship Cancer Institute at Emory University and investigator in the cemsidomide clinical trials to discuss the evolving multiple myeloma landscape, the role of IKZF1/3 degradation in treating multiple myeloma, and cemsidomide’s profile. About Cemsidomide Cemsidomide is an investigational, next-generation orally bioavailable MonoDAC® degrader (molecular glue) of IKZF1/3, transcription factors foundational to multiple myeloma biology. Data from the fully enrolled Phase 1 trial show cemsidomide’s differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity that support the potential for durable outcomes. About Multiple Myeloma Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow. It is the second most common blood cancer, with approximately 36,000 people in the United States diagnosed each year. Multiple myeloma is characterized by cycles of remission and relapse, which leads to patients needing multiple lines of therapy to manage this persistent disease. More than 175,000 patients in the United States are estimated to be living with or in remission from myeloma. However, despite treatment advances, approximately 40% of patients do not survive beyond five years. About IKZF1/3 Degradation Targeted degradation of IKZF1 (Ikaros) and IKF3 (Aiolos) is a foundational therapeutic strategy to treat multiple myeloma, a blood cancer affecting plasma cells. IKZF1/3 degradation leads to downregulation of IRF4, which promotes myeloma cell death. IKZF1/3 degradation also activates T-cells, which contributes to broader anti-myeloma response. For decades, IKZF1/3 degradation has been used in approved therapies for multiple myeloma. Next-generation IKZF1/3 degraders are being developed to leverage advances in targeted protein degradation research while continuing to address the biology foundational to multiple myeloma. About the MOMENTUM Trial MOMENTUM (Multi-center trial Of cemsidoMidE iN relapsed/refracTory mUltiple Myeloma) is a Phase 2, open-label, single-arm study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Data from the Phase 1 trial identified 100 µg as the recommended Phase 2 dose. The primary endpoint is overall response rate per International Myeloma Working Group response criteria, as assessed by an independent review committee. Approximately 100 patients who have received at least three prior anti-myeloma regimens that must have included an IKZF1/3 degrader, a proteasome inhibitor, an anti-CD38 antibody, and a
T-cell engager or CAR-T therapy will be enrolled in the trial. More information is available at clinicaltrials.gov (NCT07284758). About Cemsidomide in Combination With Elranatamab (ELREXFIO®) The Phase 1b trial is designed to evaluate the safety, tolerability and preliminary efficacy of cemsidomide and dexamethasone in combination with elranatamab, an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. Data generated from the cemsidomide Phase 1 trial in relapsed/refractory multiple myeloma demonstrate robust T-cell activation and cytokine expression across multiple doses. By activating immune T-cells, cemsidomide, when combined with a BCMAxCD3 bispecific such as elranatamab, may amplify the anti-myeloma immune response and lead to deeper and more durable responses. The study will evaluate different cemsidomide dose levels (beginning with 75 µg, with the opportunity to simultaneously explore 50 µg and 100 µg) in patients who have received one to four prior lines of therapy, which must have consisted of at least one IKZF1/3 degrader. Exclusion criteria for patients include those who have received prior treatment with a BCMA-directed T-cell engager or BCMA- directed CAR-T therapy. More information is available at clinicaltrials.gov (NCT07280013). About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com. Forward Looking Statements This press release contains “forward-looking statements” of C4 Therapeutics, Inc., within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the safety, tolerability, design and potential efficacy of our therapeutic approaches and product candidates; the predictive capability of our TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC® degraders; the potential initiation, timing, design, results and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization and guidance related to clinical trials and other clinical development activities including clinical trial commencement or cohort initiation; the potential for regulatory approval, including accelerated approval, of our product candidates; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; regulatory developments in the United States and foreign countries; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; the risk that our product candidates will not receive accelerated approval or that we will need to redesign our regulatory strategy; the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required; and the risk that the results of preclinical studies and/or clinical trials will or will not be predictive of results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and C4 Therapeutics undertakes no duty to update this information unless required by law. Contacts: Investors: Courtney Solberg Associate Director, Investor Relations CSolberg@c4therapeutics.com Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com
FAQ
What did C4 Therapeutics (CCCC) report about its cemsidomide Phase 1 trial?
C4 Therapeutics reported updated Phase 1 data for cemsidomide plus dexamethasone in 73 heavily pretreated multiple myeloma patients, showing a 53% overall response rate at the 100 µg recommended Phase 2 dose and 36% across all doses, with some deep, durable responses.
How strong were the cemsidomide response rates in relapsed/refractory multiple myeloma?
At the 100 µg once-daily recommended Phase 2 dose, cemsidomide achieved a 53% overall response rate and 63% clinical benefit rate. Across all dose levels, the overall response rate was 36%, and some patients reached minimal residual disease-negative complete responses, indicating meaningful anti-myeloma activity.
What safety profile did cemsidomide show in the Phase 1 multiple myeloma study?
Cemsidomide plus dexamethasone was generally well tolerated, with treatment-emergent events dominated by on-target neutropenia. Grade 3/4 neutropenia occurred in 58% of patients, but dose reductions were uncommon, no discontinuations were attributed to cemsidomide, and adverse events were described as manageable.
What were the progression-free survival and duration of response for cemsidomide?
Across all dose levels, median progression-free survival was 3.9 months with a 95% confidence interval of 3.2 to 5.6 months. Median duration of response was 7.9 months with a 95% confidence interval of 3.0 months to non-evaluable, reflecting durability in responders within this heavily pretreated population.
What future clinical plans did C4 Therapeutics outline for cemsidomide?
C4 Therapeutics is enrolling a Phase 2, single-arm study of cemsidomide plus dexamethasone in fourth-line and later multiple myeloma and running a Phase 1b trial combining cemsidomide, dexamethasone and the BCMAxCD3 bispecific elranatamab, aiming to support potential accelerated approval and earlier-line combinations.
How does cemsidomide fit into C4 Therapeutics’ broader strategy?
Cemsidomide is central to C4 Therapeutics’ oncology strategy as a potential best-in-class IKZF1/3 degrader and possible foundational therapy across multiple myeloma lines. The company also highlighted discovery work in inflammation, neuroinflammation and neurodegeneration, plus collaborations intended to expand its targeted protein degradation pipeline.